2024
Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease
Moses J, Adler J, Saeed S, Firestine A, Galanko J, Ammoury R, Bass D, Bass J, Bastidas M, Benkov K, Bousvaros A, Cabrera J, Chun K, Dorsey J, Ebach D, Gulati A, Herfarth H, Ivanova A, Jester T, Kaplan J, Kusek M, Leibowitz I, Linville T, Margolis P, Minar P, Molle-Rios Z, Niklinska-Schirtz B, Olano K, Osaba L, Palomo P, Pashankar D, Pitch L, Samson C, Sandberg K, Steiner S, Strople J, Sullivan J, Tung J, Wali P, Wohl D, Zikry M, Boyle B, Kappelman M. Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease. Inflammatory Bowel Diseases 2024, izae239. PMID: 39418336, DOI: 10.1093/ibd/izae239.Peer-Reviewed Original ResearchTherapeutic drug levelsPatients treated with adalimumabPatients treated with infliximabHigher drug levelsAnti-TNF levelsMedian drug levelsTreatment failureCombination therapyReduce treatment failureDrug levelsLD-MTXLow-dose oral methotrexateAssociated with treatment failureCrohn's diseaseMonotherapy to combination therapyRisk of treatment failureAnti-tumor necrosis factorEffects of combination therapyCombination therapy armMaintenance of remissionAssociated with reduced riskPediatric Crohn's diseasePost Hoc AnalysisAdalimumab initiationMaintenance therapyRates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease
Petrov J, Al-Bawardy B, Alzahrani R, Mohamed G, Fine S. Rates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease. Journal Of Clinical Gastroenterology 2024, 59: 232-236. PMID: 38595134, DOI: 10.1097/mcg.0000000000002003.Peer-Reviewed Original ResearchUstekinumab dose escalationDose-escalation groupInflammatory bowel diseaseDose escalationC-reactive proteinEndoscopic healingEscalation groupClinical remissionNormalization of C-reactive proteinSteroid-free clinical remissionBowel diseaseSerum C-reactive proteinNormalization of serum C-reactive proteinMaintenance of remissionReal-world cohortProportion of patientsUstekinumab doseMean hemoglobinBaseline albuminRetrospective studyUstekinumabMale sexMultivariate analysisPrimary outcomeSecondary outcomes
2021
Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis
Berti A, Alsawas M, Jawaid T, Prokop L, Lee J, Jeong G, Quintana L, Moiseev S, Vaglio A, Tesar V, Geetha D, Shin J, Kronbichler A. Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis. Nephrology Dialysis Transplantation 2021, 37: 2190-2200. PMID: 34910216, DOI: 10.1093/ndt/gfab357.Peer-Reviewed Original ResearchConceptsSevere adverse effectsMycophenolate mofetilKidney involvementRemission maintenanceSubgroup meta-analysisRemission-inductionMicroscopic polyangiitisFollow-upMeta-analysis of phase IIMeta-analysisOdds ratioRate of sustained remissionAntibody (ANCA)-associated vasculitisFrequency of severe adverse effectsMMF efficacySustained remission rateANCA-associated vasculitisMycophenolate mofetil useMaintenance of remissionMeta-analysis of trialsSystematic reviewPhase IIRemission rateSustained remissionIII trials
2014
Efficacy and Safety of Rituximab in Children with Refractory Nephrotic Syndrome; A Multicenter Clinical Trial
Ahn Y, Kang H, Kim S, Han K, Cho H, Shin J, Cho M, Park Y, Kim S, Lee S, Cheong H, Ha I. Efficacy and Safety of Rituximab in Children with Refractory Nephrotic Syndrome; A Multicenter Clinical Trial. Kidney Research And Clinical Practice 2014, 33: a1-a2. DOI: 10.1016/j.krcp.2014.05.017.Peer-Reviewed Original ResearchSafety of RTXStandard therapy armRefractory nephrotic syndromeRefractory NSCalcineurin inhibitorsNephrotic syndromeClinical trialsRTX treatmentTherapy armSolid evidence of efficacyAnti-CD20 Monoclonal AntibodyMulticenter open-label trialLong-term safety profileCD19 cell countsSafety of rituximabKorean pediatric patientsMaintenance of remissionPrimary end pointOpen-label trialRandomized to standard treatmentSingle-arm studyMulticenter clinical trialRandomized clinical trialsEvidence of efficacyRTX administration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply